media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Vietnam Medipharm Expo

Organiser：Ministry of Health of Vietnam Time：July 30 – August 1, 2026 Address：Lawrence S. Ting Building, 801 Nguyen Van Linh Parkway, District 7, Ho Chi Minh City, Vietnam Exhibition hall： Saigon Exhibition and Convention Center (SECC) Product range: ‌Medical Products‌: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, ambulance equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, otolaryngology equipment, dental equipment and supplies, medical reagents and equipment, healthcare products and devices, medical institution and laboratory technical equipment, medical information and technical exchange, aesthetic instruments. ‌Analytical Instruments‌: Optical analytical instruments, mass spectrometers, spectrometers, chromatographs, spectrometers, electrochemical analytical instruments, ray analytical instruments, gas chromatographs, liquid chromatographs, thermal analytical instruments, various portable instruments, surface analytical instruments, nuclear analytical instruments, elemental analytical instruments, process analytical instruments, component analytical instruments, injection analytical instruments and other general analytical instruments. ‌Laboratory Equipment‌: Laboratory instruments and equipment, laboratory automation and accessories, optical instrument equipment, microscopes, optical ...
- Source: drugdu
- 36
- July 2, 2026
【EXPERT Q&A】Compliance Information to Be Displayed on Medical Device Product Pages

Drugdu.com expert’s response: In accordance with the Quality Management Specifications for Online Sales of Medical Devices which came into effect on October 1, 2025 and relevant regulatory requirements, the following compliance information must be continuously displayed in a prominent position on the medical device product page: ‌Core Product Qualification Information‌ Images of the Medical Device Registration Certificate (for Class II and Class III devices) or the Class I Medical Device Filing Information Form, or the link identifier of the corresponding electronic certificate. ‌General Warning Information‌ For all medical devices sold online in retail mode, the warning statement “Please carefully read the product manual before purchase and use, or purchase and use it under the guidance of medical personnel” must be displayed. ‌Exclusive Warnings for Special Categories‌ For selling contact lenses (contact lenses): The mandatory warning statement “Wearing this product must be fitted by an optometry professional” must be displayed. For selling hearing aids: The mandatory warning statement “Before fitting a ...
- Source: drugdu
- 44
- July 1, 2026
AACC – Clinical Lab Expo

Organiser：American Association for Clinical Chemistry Time： July 28–30, 2026 Address：2301 S. Lake Shore Drive Chicago, Illinois 60616 USA Exhibition hall：McCormick Place Product range: In Vitro Diagnostic (IVD) Instruments & Reagents, biochemical instruments, chemical reagents, chromatographs, food safety detectors, amino acid sequencers, DNA synthesizers, microplate readers, fermentation equipment, extraction equipment, separation equipment, purification equipment, biopharmaceutical instruments & consumables, diagnostic instruments, pharmaceuticals and diagnostics, electronic and optical microscopes, spectrometers, spectrum analyzers, X-ray analytical instruments, injection analytical instruments, electrolytes, cancer testing, blood glucose testing, DNA analysis, enzymology, molecular diagnostics, hematology and hemostasis, cardiology testing, infectious disease testing, medical genomics, informatics, etc. About AACC – Clinical Lab Expo： AACC – Clinical Lab Expo, also known as the American Clinical Laboratory & In Vitro Diagnostic Exhibition, is the world’s largest and most influential annual scientific conference and clinical laboratory event. It offers attendees opportunities to connect with global leaders in clinical chemistry, molecular diagnostics, ...
- Source: drugdu
- 44
- June 30, 2026
【EXPERT Q&A】Why Do Class III Medical Device Buyers Pay More Attention to Compliance Documents?

Drugdu.com expert’s response: In medical device procurement, communication around Class III products often takes longer than for Class I or Class II products. Many suppliers may feel that buyers are asking “too many details”: registration certificates, production licenses, ISO certificates, CE/FDA documentation, test reports, clinical data, authorization letters, quality system documents, after-sales service plans… Sometimes, the full set of documents has not even been provided before pricing discussions begin. But for Class III medical device buyers, compliance documents are not an extra requirement. They are the first threshold in procurement evaluation. According to China’s Regulations on the Supervision and Administration of Medical Devices, Class III medical devices refer to products with higher risks that require special measures for strict control and management to ensure their safety and effectiveness. Risk classification takes into account factors such as intended use, structural characteristics, and method of use. In other words, Class III products ...
- Source: drugdu
- 50
- June 29, 2026
【Company Recommendation】Emeishan Hongsen Biopharmaceutical Co., Ltd.

Company Introduction Emeishan Hongsen Biopharmaceutical Co., Ltd. is a national high-tech enterprise focusing on peptide fragments, protected amino acids, pharmaceutical intermediates, APIs, and CMO/CDMO fields. Business scope: an experienced project undertaking team escorts full life-cycle CMO/CDMO services; a GMP quality system that has been audited many times by domestic and foreign customers; the company has an independent technology R&D center, a provincial enterprise technology center, and Leshan Synthetic Biology Engineering Technology Research Center, providing one-stop services including process optimization, R&D, production, and sales. The company was established on February 18, 2011. It currently has more than 150 employees and more than 70 sets of various reactors ranging from 100L to 6300L, providing flexible and diversified cooperation models. Star Products 89030-95-5 Copper Peptide Copper peptide can effectively stimulate the biosynthesis of collagen in fibroblasts, thereby promoting rapid wound healing. It can also effectively block the neurotransmission of acetylcholine substances, thereby relaxing ...
- Source: drugdu
- 63
- June 26, 2026
China’s first ADC (Advanced Dioxide Doppler) to be submitted for market approval

On June 23, the CDE (Center for Drug Evaluation) website showed that Chia Tai Tianqing Pharmaceutical Group’s application for marketing authorization of vetectobactimab for injection was accepted. This monotherapy is indicated for patients with CLDN18.2-positive, locally advanced, or metastatic gastric/gastroesophageal junction adenocarcinoma who have received at least two lines of prior systemic therapy . Previously, this drug had been formally included in the CDE’s priority review and approval process . Screenshot source: CDE official website Vitacotobactam (development code: LM-302 ) is an antibody-drug conjugate (ADC) targeting Claudin18.2 (CLDN18.2) developed by Lixin Pharmaceuticals. It specifically binds to CLDN18.2-positive tumor cells, enters the cells via endocytosis, and releases small molecule toxins to achieve precise killing of tumor cells. In July 2025, China Biopharmaceutical announced that it would acquire 100% of Lixin Pharmaceutical Technology (Shanghai) Co., Ltd. for a net consideration of approximately US$500 million , bringing the latter’s highly regarded bispecific antibody ...
- Source: drugdu
- 73
- June 25, 2026
Sanofi’s second autoimmune BTK inhibitor approved for marketing

On June 23, Sanofi announced that Tolebrutinib (trade name: Cenrifki) has been approved by the European Medicines Agency (EMA) for the treatment of relapse-free secondary progressive multiple sclerosis (SPMS). This drug is the first approved treatment for non-relapsing SPMS and Sanofi’s second approved autoimmune BTK inhibitor. Sanofi’s first autoimmune BTK inhibitor, Rilzabrutinib (trade name: Wayrilz ), was approved in the US and Europe in 2025.This approval was supported by the Phase III HERCULES study , which included 1131 patients with non-recurrent SPMS .Patients. Results showed that at a median follow-up of 133 weeks, the proportion of patients in the Tolebrutinib (60 mg, once daily) group who had confirmeddisability progression lasting at least 6 months was significantly lower than that inthe placebo group (22.6% vs 30.7%, HR=0.69, P=0.003).Multiple sclerosis (MS) is a chronic, immune-mediated neurodegenerative disease of the central nervous system that can lead to persistent and irreversible disability over time. ...
- Source: drugdu
- 69
- June 25, 2026
Qingfeng Pharmaceutical’s apalutamide tablets have been approved, adding another powerful tool to the field of anti-tumor therapy

According to the official website of the National Medical Products Administration (NMPA), the generic apalutamide tablets submitted by Kerui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, were approved for production on May 19 and are considered to have passed the consistency evaluation. This is the third endocrine therapy chemical drug approved for Qingfeng Pharmaceutical, marking a new milestone in the company’s R&D and commercialization strategy in the field of prostate cancer treatment. 0 1 Apalutamide tablets: A new generation of androgen receptor inhibitors Blockbuster drugs for prostate cancer treatment Apalutamide is a new generation of oral, highly selective nonsteroidal androgen receptor (AR) inhibitors. It competitively blocks androgen binding by binding to the intracellular ligand-binding domain of AR with high affinity, inhibiting receptor conformational changes and nuclear translocation, and preventing AR translocation into the nucleus.<sup> 1 </sup> Simultaneously, it blocks the binding of AR to DNA response elements, inhibiting the transcription ...
- Source: drugdu
- 65
- June 25, 2026
PHARMCHINA——tHIS ASEAN

Organiser：Sinopharm Exhibition & APHM Time： July 28–30, 2026 Address：Kuala Lumpur Convention Centre, Kuala Lumpur City Centre, Kuala Lumpur, 50088, Malaysia Exhibition hall：Kuala Lumpur Convention Centre, Kuala Lumpur City Centre Product range: Pharmaceuticals: Chemical drugs, Chinese patent medicines, ethnic medicines, OTC drugs, biological products Pharma R&D Supply Chain: R&D services, CRO, CMO, CDMO, MAH cooperation, registration consulting Chinese Herbal Medicines / Prepared Slices: Bulk herbal slices, traditional prepared slices, refined-packaging slices, small-packaging slices, direct-oral solid slices, wall-broken slices, food-medicine homology herbs & herbal teas, TCM formula granules, new-type prepared slices, raw Chinese herbs, TCM slice production equipment, TCM slice packaging, etc. TCM Wellness: Moxibustion & moxa products, TCM wellness clinics, foot bath & medicinal bath products, TCM beauty, Chinese medicinal oils/ointments, medicinal cuisine, health wine, etc. TCM Diagnostic & Treatment Equipment: TCM diagnostic equipment, TCM instruments, TCM pharmaceutical equipment, etc. Public Health & Protection: Masks, gloves, protective suits, goggles, disinfection products, ...
- Source: drugdu
- 60
- June 23, 2026
【EXPERT Q&A】What certifications are required for medical devices to enter the Saudi market?

Drugdu.com expert’s response: The core of entering the Saudi market is mandatory registration and certification with the Saudi Food and Drug Authority (SFDA), along with a series of supporting requirements. The following breaks them down by priority. I. Core Certification That Must Be Completed: SFDA Medical Device Registration This is the only legal entry requirement for all medical devices. Unregistered products cannot clear customs or be sold. Registration Process: Submit registration application through the SFDA online system (MDMA / Saudi Drug Registration System) Submit complete technical documentation; SFDA conducts document review Medium-to-high risk products may be required to provide additional test reports or undergo on-site audits Upon approval, a registration certificate is issued (typically valid for 5 years, renewable upon expiry) II. Products Classified by Risk Level — Requirements Differ SFDA classifies medical devices into four classes. The higher the class, the stricter the review: Class I (Low Risk) — e.g., surgical blades, ...
- Source: drugdu
- 66
- June 22, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.